PT  - JOURNAL ARTICLE
AU  - YOSHIHIRO YAMAMOTO
AU  - KAZUSHI WATANABE
AU  - IKUTO TSUKIYAMA
AU  - HIROMITSU YABUSHITA
AU  - KATSUHIKO MATSUURA
AU  - AKIHIKO WAKATSUKI
TI  - Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m<sup>2</sup>) Combination Chemotherapy
DP  - 2016 Apr 01
TA  - Anticancer Research
PG  - 1873--1877
VI  - 36
IP  - 4
4099  - http://ar.iiarjournals.org/content/36/4/1873.short
4100  - http://ar.iiarjournals.org/content/36/4/1873.full
SO  - Anticancer Res2016 Apr 01; 36
AB  - Aim: We aimed to assess whether the efficacy of pre-hydration with 15 mEq magnesium prevents cisplatin-induced nephrotoxicity in cisplatin regimens (dosage: 50 mg/m2 or more) for gynecological cancer. Patients and Methods: This historical, prospective cohort study compared nephrotoxicity in patients who received pre-hydration with or without magnesium sulfate (Mg-hydration group, n=37; non-Mg-hydration group, n=37). We used serum creatinine (Scr), creatinine clearance (Ccr) and Risk, Injury, Failure, Loss of kidney function and End-stage kidney disease (RIFLE) criteria. Results: A change of Scr and Ccr in the Mg-hydration group was higher than in the non-Mg-hydration group. Based on the RIFLE criteria, the number of moderate renal dysfunction patients classified as “Risk” in the Mg-hydration group was significantly lower than in the non-Mg-hydration group (Mg-hydration group=21.6%; non-Mg-hydration group=51.4%; p<0.01). Serum magnesium levels in the Mg-hydration group significantly declined during chemotherapy (p<0.01). Conclusion: We found that a 15 mEq magnesium as pre-hydration provided nephroprotective effects in patients receiving this cisplatin regimen. Future research should involve finding appropriate magnesium doses.